Research Article
Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib
Table 2
Patient characteristics.
| | All patients | IPSS category | | | Low risk | Intermediate-1 risk | | % | | % | | % |
| Total patients | 108 | 100.00 | 25 | 100.00 | 83 | 100.00 | Age | | | | | | | ≤65 years | 91 | 84.26 | 25 | 100.00 | 66 | 79.52 | >65 years | 17 | 15.74 | 0 | 0.00 | 17 | 20.48 | Sex | | | | | | | Male | 72 | 66.67 | 15 | 60.00 | 57 | 68.67 | Female | 36 | 33.33 | 10 | 40.00 | 26 | 31.33 | Race or ethnicity | | | | | | | White | 79 | 73.15 | 21 | 84.00 | 58 | 69.88 | Black | 16 | 14.81 | 2 | 8.00 | 14 | 16.87 | Hispanic | 10 | 9.26 | 0 | 0.00 | 10 | 12.05 | Other | 2 | 1.85 | 1 | 4.00 | 1 | 1.20 | Do not know | 1 | 0.93 | 1 | 4.00 | 0 | 0.00 | Primary insurance type at ruxolitinib initiation | | | | | | | Commercial | 43 | 39.81 | 10 | 40.00 | 33 | 39.76 | Medicare | 47 | 43.52 | 9 | 36.00 | 38 | 45.78 | Medicaid | 9 | 8.33 | 2 | 8.00 | 7 | 8.43 | Uninsured | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | Other | 2 | 1.85 | 0 | 0.00 | 2 | 2.41 | Do not know | 7 | 6.48 | 4 | 16.00 | 3 | 3.61 | MF type at diagnosis | | | | | | | Primary MF | 88 | 81.48 | 20 | 80.00 | 68 | 81.93 | Postpolycythemia vera MF | 10 | 9.26 | 3 | 12.00 | 7 | 8.43 | Postessential thrombocythemia MF | 9 | 8.33 | 2 | 8.00 | 7 | 8.43 | Do not know | 1 | 0.93 | 0 | 0.00 | 1 | 1.20 | JAK2 V617F mutation test result | | | | | | | Positive | 74 | 68.52 | 14 | 56.00 | 60 | 72.29 | Negative | 21 | 19.44 | 7 | 28.00 | 14 | 16.87 | Test not done | 3 | 2.78 | 1 | 4.00 | 2 | 2.41 | Do not know | 10 | 9.26 | 3 | 12.00 | 7 | 8.43 | Charlson comorbidities at ruxolitinib initiation | | | | | | | Hypertension | 35 | 32.41 | 6 | 24.00 | 29 | 34.94 | Diabetes (overall) | 17 | 15.74 | 2 | 8.00 | 15 | 18.07 | Diabetes (without end organ damage) | 15 | 13.89 | 1 | 4.00 | 14 | 16.87 | Chronic pulmonary disease | 9 | 8.33 | 1 | 4.00 | 8 | 9.64 | Liver disease (overall) | 7 | 6.48 | 1 | 4.00 | 6 | 7.23 | Depression | 7 | 6.48 | 0 | 0.00 | 7 | 8.43 | Mild liver disease | 6 | 5.56 | 1 | 4.00 | 5 | 6.02 | Cerebrovascular disease | 5 | 4.63 | 1 | 4.00 | 4 | 4.82 | Connective tissue disease | 4 | 3.7 | 1 | 4.00 | 3 | 3.61 | Dementia | 3 | 2.78 | 0 | 0.00 | 3 | 3.61 | Malignant solid tumor | 3 | 2.78 | 1 | 4.00 | 2 | 2.41 | HIV/AIDS | 2 | 1.85 | 0 | 0.00 | 2 | 2.41 | Hemiplegia | 2 | 1.85 | 0 | 0.00 | 2 | 2.41 | Myocardial infarction | 2 | 1.85 | 0 | 0.00 | 2 | 2.41 | Diabetes (with end organ damage) | 2 | 1.85 | 1 | 4.00 | 1 | 1.20 | Malignant lymphoma | 1 | 0.93 | 0 | 0.00 | 1 | 1.20 | Moderate or severe liver disease | 1 | 0.93 | 0 | 0.00 | 1 | 1.20 | Peripheral vascular disease | 1 | 0.93 | 0 | 0.00 | 1 | 1.20 | Ulcer disease | 1 | 0.93 | 1 | 4.00 | 0 | 0.00 | Congestive heart failure | 0 | 0 | 0 | 0.00 | 0 | 0.00 | None of these | 36 | 33.33 | 11 | 44.0 | 25 | 30.12 | Other | 0 | 0.00 | 0 | 0.0 | 0 | 0.00 | Do not know | 8 | 7.41 | 4 | 16.0 | 4 | 4.82 | Ruxolitinib doses utilized | | | | | | | Starting median daily dose, mg (min, max) | 30 (2, 56) | 30 (4, 56) | 30 (2, 50) | Dose range observed over entire treatment duration, (min, max) | 2, 60 | 4, 60 | 2, 50 | Still on ruxolitinib at last available follow-up? | | | | | | | Yes | 87 | 80.60 | 23 | 92.00 | 64 | 77.10 | No | 15 | 13.90 | 2 | 8.00 | 13 | 15.70 | Do not know | 6 | 5.60 | 0 | 0.00 | 6 | 7.20 |
|
|
IPSS, International Prognostic Scoring System; JAK2, Janus kinase 2; MF, myelofibrosis.
|